Skip to main content

Table 1 Demographic and disease profile

From: Evaluation of tumor M2-pyruvate kinase (Tumor M2-PK) as a biomarker for pancreatic cancer

Age (median––range) 66 (23–83)
Gender Male 52 (71%)
Female 21 (29%)
Management
 Surgical treatment 65 (89%)
  Resection 55
   Pancreaticoduodenectomy 47
   Distal pancreatectomy + splenectomy 5
   Total pancreatectomy 2
   Central pancreatectomy 1
  No resection 10
   Palliative procedures 8
   Intraoperative biopsy only 2
 No surgical treatment 8 (11%)
Histology of resected specimen  
 Malignant 46 (63%)
  Pancreatic ductal adenocarcinoma 18
  Ampullary adenocarcinoma 15
  Neuroendocrine tumor 6
  Distal bile duct cholangiocarcinoma 4
  Duodenal adenocarcinoma 2
  Pancreatic adenosquamous carcinoma 1
 Benign 9 (12%)
  Groove pancreatitis 2
  Chronic pancreatitis 2
  Ampullary tubulovillous adenoma 2
  Mucinous neoplasm 1
  Serous cystadenoma 1
  Solid pseudopapillary tumor 1
 Histology/cytology from biopsy 18 (25%)
  Pancreatic ductal/ampullary adenocarcinoma 8
  Neuroendocrine tumor 1
  Adenocarcinoma (frozen section) 5
  Histology not confirmed (clinical/radiological diagnosis) 4
Cancer differentiationa
  Well and moderately differentiated 34
  Poorly differentiated 16
Resection marginb
  R0 18
  R1 28
  1. R0 complete histological resection with at least 1-mm clear resection margin. R1 tumor reaches surgical resection margin
  2. aAvailable for 46 patients who underwent resection and a further 4 who underwent biopsy
  3. bApplies only to patients undergoing surgical resection for cancer
  4. The values in italics denote statistical significance